March 22, 2018
Applied Clinical Trials Volume 27, Issue 3 The market viability of orphan drugs—pharmaceuticals targeting rare diseases and disorders—has gained significant traction in recent years, generally from the lack of competition and high financial rewards. However, the risk is significant and finding patients to monetize the investment makes it a precarious business. What we know for...
Read More
Skip to content